Versant-backed Ventus scores $100M round to turbocharge its dual-platform play at 'drugging the undruggable'
If one thing is true in biopharma venture capital, it’s that investors love a platform play. Now, a biotech with personnel split across the US …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
